U.S. markets close in 6 hours 6 minutes
  • S&P 500

    3,941.46
    +41.35 (+1.06%)
     
  • Dow 30

    31,801.29
    +363.03 (+1.15%)
     
  • Nasdaq

    11,614.84
    +90.29 (+0.78%)
     
  • Russell 2000

    1,786.43
    +14.69 (+0.83%)
     
  • Crude Oil

    110.91
    +1.34 (+1.22%)
     
  • Gold

    1,823.40
    -1.40 (-0.08%)
     
  • Silver

    21.10
    -0.07 (-0.32%)
     
  • EUR/USD

    1.0539
    -0.0048 (-0.45%)
     
  • 10-Yr Bond

    3.2130
    +0.0190 (+0.59%)
     
  • GBP/USD

    1.2217
    -0.0053 (-0.43%)
     
  • USD/JPY

    136.2480
    +0.8020 (+0.59%)
     
  • BTC-USD

    21,080.88
    +235.21 (+1.13%)
     
  • CMC Crypto 200

    460.96
    +10.90 (+2.42%)
     
  • FTSE 100

    7,351.98
    +93.66 (+1.29%)
     
  • Nikkei 225

    27,049.47
    +178.20 (+0.66%)
     

Regulus Starts Preclinical Studies In ALS Under Pact With Brigham and Women's Hospital

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Regulus Therapeutics Inc (NASDAQ: RGLS) has initiated studies to evaluate a library of oligonucleotides to block miR-155 for Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) under a collaboration agreement with Harvard's Brigham and Women's Hospital (BWH).

  • The agreement, effective since September 2021, encompasses the investigation of the biologic effects of miR-155 inhibitors in both in vitro and in vivo models of ALS.

  • Results from these initial studies will guide future experiments' design in additional animal models of the disease and characterize their properties.

  • Preliminary data from the studies are expected in 2H of 2022.

  • In animal models of ALS, miR-155 was found upregulated in microglia and associated with disease progression. Notably, miR-155 was also elevated in the spinal cord of patients with ALS.

  • Anti-miR-155 treatment suppressed disease-associated cytotoxic microglia, and resulted in robust improvement in clinically relevant disease endpoints, including prolongation of survival.

  • Price Action: RGLS shares are up 1.08% at $0.29 during the market session on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.